A Setting Focus Overdose Prevention Intervention (Oasis)

A Geospatial Analysis of Hotspots and Targeted Injection Settings Pilot Intervention for HIV Prevention Among People Who Inject Drugs in Baltimore, Maryland

A pilot injection-setting targeted peer-driven intervention to reduce HIV and hepatitis C virus transmission and overdose risk behaviors among people who inject drugs (PWID).

Study Overview

• Status: Recruiting
• Conditions: HIV Infections; Drug Overdose; HCV
• Intervention / Treatment: Behavioral: HIV, HCV and overdose prevention

Detailed Description

This is a pilot of an injection setting targeted peer-driven intervention to reduce HIV/HCV transmission and overdose risk behaviors. Participants will be randomized to conditions: 1) Peer education and stocking of semi-public injection settings (SPIS) with risk reduction materials, and the standard of care. Based on their SPIS use, 120 index PWID participants will be selected.

A conceptual model for the intervention: The conceptual model is based on social influence, social network, and social cognitive theory. The prior work delineated social influence mechanisms. It is expected that training and modeling of effective communication skills will increase the occurrence of conversations on HIV/HCV and overdose prevention. These conversations will then alter perceived descriptive and prescriptive social norms of risk behaviors. The prior work is being enhanced by increasing the availability of risk reduction materials as well as the cuing and modeling risk reduction behaviors in risk settings. It has been found that PWID are motivated to conduct peer education; it enhances their status and provides them a prosocial role in the community. It is hypothesized that peer outreach and supply of materials to SPIS will lead to reduced sharing of injection equipment and increased naloxone availability.

• Study Type: Interventional
• Enrollment (Estimated): 285
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Carl Latkin, PhD; Phone Number: 410-955-3972; Email: carl.latkin@jhu.edu
• Study Contact Backup: Name: Lauren Dayton, PhD; Phone Number: 4105025368; Email: ldayton2@jhu.edu

Study Locations

• United States
  • Maryland
    • Baltimore, Maryland, United States, 21205
      • Recruiting
      • Lighthouse Studies at Peer Point
      • Contact: Carl Latkin, PhD; Phone Number: 410-502-5368; Email: carl.latkin@jhu.edu
      • Contact: Melissa Davey-Rothwell, PhD; Phone Number: 410-614-5854; Email: mdavey1@jhu.edu
      • Principal Investigator: Carl Latkin, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Current drug user (opioid use in the prior two weeks)

Exclusion Criteria:

• Any mental or physical health impairment that impedes ability to participate

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental; behavioral training with 6 sessions	Behavioral: HIV, HCV and overdose prevention; HIV, HCV and overdose prevention
Active Comparator: comparison; Attention control	Behavioral: HIV, HCV and overdose prevention; HIV, HCV and overdose prevention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overdose prevention	Frequency of carrying naloxone	6 months
HIV/HCV prevention	Frequency of using used cookers	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overdose behaviors	Frequency of testing drugs before using	6 months
Overdose behaviors 2	Frequency of talking about overdose prevention	6 months

Collaborators and Investigators

• Sponsor: Johns Hopkins Bloomberg School of Public Health
• Collaborators: National Institute on Drug Abuse (NIDA)
• Investigators: Principal Investigator: Carl Latkin, PhD, Johns Hopkins Bloomberg School of Public Health

Study record dates

Study Major Dates

• Study Start (Actual): April 30, 2022
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): May 30, 2027

Study Registration Dates

• First Submitted: March 30, 2022
• First Submitted That Met QC Criteria: April 8, 2022
• First Posted (Actual): April 11, 2022

Study Record Updates

• Last Update Posted (Actual): May 22, 2026
• Last Update Submitted That Met QC Criteria: May 19, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Blood-Borne Infections; Urogenital Diseases; Genital Diseases; Drug Misuse; Mental Disorders; Immune System Diseases; Infections; RNA Virus Infections; Virus Diseases; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; Substance-Related Disorders; Chemically-Induced Disorders; Prescription Drug Misuse; HIV Infections; Drug Overdose; Immune System Phenomena; Seroconversion
• Other Study ID Numbers: R01DA050470 (U.S. NIH Grant/Contract); IRB00019139 (Other Identifier: JHSPH IRB)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No